Psychosis from Anticholinergic medications administered at a smoking cessation clinic

Journal of Pharmacy Practice

Volumn 22, Issue 5, 2009, Pages 489-493

  Minton, Jenna A ^a   Tofade, Toyin S ^b   Shah, Sidharth A ^c  

^a Wake Area Health Education Center   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Anticholinergics; Delirium; Hallucinations; Psychosis; Scopolamine; Smoking cessation; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; ATROPINE; BELLADONNA ALKALOID; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATININE; FLUTICASONE PROPIONATE PLUS SALMETEROL; INFUSION FLUID; LORAZEPAM; MONTELUKAST; NICOTINE; PAROXETINE; PHENOBARBITAL; POTASSIUM; PROPANTHELINE BROMIDE; SALBUTAMOL; SCOPOLAMINE; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; AUDITORY HALLUCINATION; BLURRED VISION; CASE REPORT; CREATININE BLOOD LEVEL; EMERGENCY WARD; HERPES ZOSTER OTICUS; HUMAN; KIDNEY FAILURE; MALE; MENTAL HEALTH; NAUSEA; PARANOIA; POTASSIUM BLOOD LEVEL; PSYCHOSIS; RHABDOMYOLYSIS; SIDE EFFECT; SMOKING CESSATION; TACHYCARDIA; TACHYPNEA; VERTIGO; VISUAL HALLUCINATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 70649114434     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008330201     Document Type: Article

References (12)

1. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw Hill Medical Publishing Division; 2001:162-168.
2. Peters ML. Snipping the thread of life: Antimuscarinic side effects of medications in the elderly. Arch Intern Med. 1989;149:2414-2420.
3. Bachynsky N. The use of anticholinergic drugs for smoking cessation: a pilot study. Int J Addict. 1986;21: 789-805.
4. Scopolamine monograph. American Hospital Formulary Service. Available at: http://online.statref.com/Document/Document.aspx?DocId=337&FxId= 1&Scroll=1&Index=0&SessionId=DEA987CJRTGYBYPY. Accessed November 18, 2008.
5. Physostigmine monograph. American Hospital Formulary Service. Available at: http://online.statref.com/Document/Document.aspx?DocId=322&FxId= 1&Scroll=1&Index=1&SessionId=DEA987CJRTGYBYPY. Accessed November 18, 2008.
6. Noyan MA, Elbi H, Aksu H. Donepezil for anticholinergic drug intoxication: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:885-887.
7. Rodysill KJ, Warren JB. Transdermal scopolamine and toxic psychosis. Ann Intern Med. 1983;98:561.
8. Osterholm RK, Camoriano JK. Transdermal scopolamine psychosis. JAMA. 1982;247:3081.
9. Ziskind AA. Transdermal scopolamine-induced psychosis. Postgrad Med. 1988;84:73-76.
10. Mego DM, Omori DJM, Hanley JF. Transdermal scopolamine as a cause of transient psychosis in two elderly patients. South Med J. 1988;81:394-395.
11. Clarke LA, Cassidy CW, Catalano G, Catalano MC, Carroll KM. Psychosis induced by smoking cessation clinic administered anticholinergic overload. Ann Clin Psych. 2004;16:171-175.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.